Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 injection (BNT327) plus mFOLFOX6/CAPEOX as first-line therapy for MSS or MSI-L/pMMR metastatic colorectal cancer
CTR20251974Phase 2Active
- Sponsor
- Biotheus
- Start
- Aug 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pumitamig in colorectal cancer (CRC), sponsored by Biotheus. Started Aug 2025; status: active.
02
Drugs
pumitamig
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20251974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251974.